Ask about this productRelated genes to: GABRA5 antibody
- Gene:
- GABRA5 NIH gene
- Name:
- gamma-aminobutyric acid type A receptor alpha5 subunit
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 15q12
- Locus Type:
- gene with protein product
- Date approved:
- 1992-08-07
- Date modifiied:
- 2016-02-04
Related products to: GABRA5 antibody
Related articles to: GABRA5 antibody
- Late-life depression (LLD) is a debilitating condition, characterized by mood disturbance and cognitive decline. Gamma-aminobutyric acidergic (GABAergic) deficits are a hallmark of both aging and depression; however, few studies have examined the GABAergic system in LLD. We hypothesized that there would be significant decrease in peripheral GABA levels and γ-aminobutyric acid type A (GABA-A) receptor subunit expression in individuals with LLD compared to healthy controls (HC). In this study, we measured plasma GABA levels and the mRNA expression of four GABA-A receptor subunits (GABRA1, GABRA4, GABRA5, and GABRR2) in peripheral blood mononuclear cells (PBMCs) from 87 older adults (LLD, n = 46; HC, n = 41). Plasma GABA levels were quantified using enzyme-linked immunosorbent assay (ELISA), and receptor subunit expression was assessed by quantitative-real time (RT-qPCR). There were no significant differences between LLD and HC in plasma GABA levels or GABA-A receptor subunit expression. In LLD, within-group analyses showed GABRA5, GABRR2, GABRA4, GABRA1 expression were negatively correlated with cognitive performance on the Montreal Cognitive Assessment MoCA scores (ρ = -0.464, p = 0.045, ρ = -0.515, p = 0.041; ρ = -0.414, p = 0.078, and ρ = -0.477, p = 0.062 respectively). This is the first study that investigated GABA-A receptor subunit expression in the periphery of individuals with LLD. Our findings suggest that altered peripheral GABA-A receptor subunit expression, even in the absence of between-group differences, is associated with reduced cognitive function in LLD. - Source: PubMed
Publication date: 2026/05/03
Rezaei SaraSibille EtienneVoineskos DaphneRajji Tarek KNikolova Yuliya SDiniz Breno SVieira Erica L - Impulsivity is an understudied area of post-traumatic stress disorder, a debilitating disorder specifically associated with stress. We examined reward-related impulsive behavior, anxiety-like behavior, locomotor activity and social behavior in the absence and presence of protracted pharmacological positive modulation of α5- and α6-GABA receptors (GL-II-73 and DK-I-56-1, respectively) in male Sprague-Dawley rats exposed to a combination of maternal deprivation (MD) and single prolonged stress (SPS). While locomotor and anxiety-like behavior were not affected in the SPS and MD+SPS groups, the double-hit group treated with DK-I-56-1 exhibited a higher locomotor distance compared with MD+SPS and a higher percentage of open-arm time in the elevated plus maze compared with the control group. In the variable delay-to-signal task of impulsivity, the total number of successful trials and premature responses (PR) in the first stage of the test day were reduced in all groups exposed to stress compared with the controls. Based on PR rates in the first and second set of trials, motor impulsivity was apparently suppressed in all stressed groups, while delay intolerance was suppressed only in the MD+SPS+GL-II-73 group, respectively. In the three-chamber test, social interaction was completely normal, while social recognition was preserved in the MD+SPS+GL-II-73 group. In the resident-intruder test, social play was reduced only in the SPS group. The evaluation of impulsive behavior in the used complex task was hindered by the lack of motivation of stressed rats, which in the case of omission percentage was ameliorated by positive modulation of α5 and α6 GABA receptors. - Source: PubMed
Đorović ĐorđeAranđelović JovanaIvanović JanaJezdić KristinaBatinić BojanSharmin DisharyMondal PrithuCook James MSavić Miroslav M - Autism spectrum disorder (ASD) lacks validated laboratory markers for diagnosis or risk stratification. Astrocyte-linked glutamatergic regulation and GABAergic signaling may be altered in ASD. This exploratory study quantified plasma excitatory amino acid transporter 2 (EAAT2), γ-aminobutyric acid (GABA), and the GABA receptor α5 subunit (GABRA5) and described their apparent discriminative performance. In a case-control sample of 46 male participants with ASD and 26 age-matched typically developing male controls, plasma biomarkers were measured by ELISA. Group differences were assessed with nonparametric tests. Receiver operating characteristic (ROC) analyses summarized discrimination. Logistic regression was used solely to generate combined-marker ROC curves; coefficients were not interpreted. EAAT2 and GABA concentrations were lower in ASD than controls (both P < 0.001). GABRA5 was directionally lower but not statistically significant (P = 0.149). Individual AUCs were 0.952 for EAAT2, 0.827 for GABA, and 0.646 for GABRA5. Combined-marker models yielded high apparent AUCs (EAAT2 + GABA+GABRA5: 0.993) within this dataset. Lower plasma EAAT2 and GABA are associated with ASD status in this male sample. Combined markers show high apparent discrimination in a case-control design, but estimates are optimism-biased and not diagnostic. Replication with comprehensive assay validation, calibration, and clinically representative cohorts (including females and relevant differentials) is required. - Source: PubMed
Publication date: 2026/03/25
El-Ansary AfafAlabdali AltafBacha Abir BenAlonazi MonaAl-Ayadhi Laila YBjørklund Geir - Postoperative cognitive dysfunction (POCD) is a frequent complication in elderly patients that delays recovery and increases long-term health risks. Preemptive analgesia may alleviate surgery-induced inflammation and central sensitization, but its role in improving postoperative neurocognitive disorder (PND) through modulation of hippocampal Gamma-aminobutyric acid type A (GABAA) receptor α1/α5 subunits in aged rats with mild cognitive impairment (MCI) remains unclear. - Source: PubMed
Publication date: 2026/03/06
Ren HongyanZhang LinYang ChenyiWang XinyiLiu XingWang Haiyun - Dysfunction in the GABAergic system has been described in schizophrenia, including decreased expression of α5 subunit-containing GABA receptors (α5-GABARs) in patients with schizophrenia. This study explores the therapeutic potential of positive allosteric modulators (PAMs) of the α5-GABAR to reduce the hyperdopaminergic state produced by the neurodevelopmental methylazoxymethanol acetate (MAM) model of schizophrenia. Male offspring rats generated from pregnant females injected with saline or MAM at gestational day 17 were used for the electrophysiological recordings as adults. In vivo electrophysiological recordings were performed to assess the effects of 10 mg/kg of the novel α5-GABAR-preferring PAM alogabat on dopamine (DA) neuron activity in the ventral tegmental area (VTA); a dose shown to produce sustained, ≥80% α5-GABAR occupancy over a time period of 0.5-3.5 h post-dose. A less extensive confirmatory study was also performed with a second α5-GABAR PAM, Compound 100. The primary outcome was that at a dose of 10 mg/kg, which corresponded to an α5-GABAR occupancy of ≥80% for alogabat and 70% for Compound 100, reversed the increased number of spontaneously active DA neurons in MAM rats. Alogabat data showed that these effects were driven by a reduction in the central and lateral (but not medial) portions of the VTA; regions that project to the associative striatum. These findings suggest that selective targeting of α5-GABARs may help normalize aberrant DA activity. The study highlights α5-GABARs as a promising therapeutic target, potentially addressing positive symptoms by restoring excitatory-inhibitory balance in a key region of the brain implicated in the pathophysiology of schizophrenia. - Source: PubMed
Publication date: 2026/02/17
Uliana Daniela LPopa Mariana OParadowski MichaelElvers Karen THanley MarcusBaldwin AlexAtack John RGrace Anthony A